Trial Profile
A Phase 1/2 Study of Pegzilarginase (AEB1102, Co-ArgI-PEG) in Combination With Pembrolizumab in the Treatment of Patients With Extensive Disease (ED) Small Cell Lung Cancer (SCLC)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 24 Jan 2024
Price :
$35
*
At a glance
- Drugs Pegzilarginase (Primary) ; Pembrolizumab (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Aeglea Biotherapeutics; Spyre Therapeutics
- 27 Nov 2023 According to Spyre Therapeutics media release, Aeglea Biotherapeutics has changed its name to Spyre Therapeutics
- 15 Jan 2021 Status changed from active, no longer recruiting to completed.
- 06 Aug 2019 According to an Aeglea Biotherapeutics media release, the company intends on submitting the results for presentation or publication after the final dataset becomes available.